The Morgo Podcast

Blackcurrent's energy trading platform lets users manage their electricity use and selling electricity back into the grid using smart controls to shift and optimise energy use. In New Zealand it has a partnership with Farmlands for the rural sector. It is now planning to grow into Australia and Asia through partners. Pegs talks about the value of having been part of a successful startup before and about the challenges of leading as the team grows.  www.blackcurrent.io  

Cetogenix uses hydrothermal oxidation to transform organic waste into renewable natural gas, green chemicals & biomaterials. Trevor talks about the large opportunity, especially in Europe where Anglian Water is leading a $23 M collaborative project to build a demonstration scale plant. The technology and team came out of Scion Research. Trevor is loving the move from a large organisation to a small, focused team & says he should have done this 20 years earlier.  www.cetogenix.co.nz   

Ben Calvert is CEO of Flicket, an event commerce platform helping sports teams, festivals and major events sell more tickets, own their customer data and build stronger fan relationships. Ben and his co-Founders started Flicket in New Zealand and have since expanded the business across Australia, the US and the UK. Ben shares the realities of scaling internationally, the challenges along the way and what he's learned about building and hiring great teams in new markets.  www.flicket.io 

VXT automates AI notes from calls and meetings for lawyers. When Luke & co-founder Lucy Turner learned how much time lawyers spent recording time and notes from calls, they set out to solve the problem by building a phone system that integrates with legal software. Luke talks about getting customers on board, expanding offshore, the skills he brings to the role and the need to choose a co-founder carefully. VXT now has ARR of $10M and is growing at 10% per month. www.vxt.co.nz

Mars Bioimaging has developed a mobile colour CT for high quality scanning of hands and wrists. It has FDA approval in the US and is selling to the orthopaedic & emergency markets in the US & NZ. Ojas became CEO to focus on the commercialisation of the product and lead the push into the market. Key lessons: find your customer (a large market) and only then start throwing money at it. You'll fail a lot more than you win – you need to push through.  www.marsbioimaging.com